Product Description
an inhibitor of alcohol dehydrogenase. Fomepizole appears to be safe and effective in the treatment of methanol poisoning. (Sourced from: https://www.nejm.org/doi/full/10.1056/nejm200102083440605)
Mechanisms of Action: ADH Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Belgium | Canada | Czech | Finland | France | Germany | Greece | Iceland | India | Ireland | Japan | Malta | Netherlands | New Zealand | Norway | Slovenia | Sweden | Taiwan | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Chemical and Drug Induced Liver Injury|Drug Overdose|Liver Failure
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCT05517668 | P2 |
Recruiting |
Chemical and Drug Induced Liver Injury|Liver Failure|Drug Overdose |
2025-08-31 |